Press Releases

CRANBURY, N.J., April 3, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced the presentation of a poster on preclinical studies of an oral formulation of PL-8177, a selective melanocortin receptor 1 […]

Feb 12, 2018, 07:30 ET CRANBURY, N.J., Feb. 12, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2017.  Recent Highlights Bremelanotide – Under development

Feb 07, 2018, 04:00 ET CRANBURY, N.J., Feb. 7, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2018 operating results on Monday, February 12, 2018  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

CRANBURY, N.J., Feb. 5, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the first healthy subjects have been dosed in a Phase 1 clinical study of PL-8177. The Phase 1

CRANBURY, N.J., Jan. 3, 2018 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the U.S. Food and Drug Administration (FDA) has notified Palatin that it may proceed with its clinical investigation of

Palatin to Receive $500,000 Upfront Entitled to Receive $3.0 Million on First Commercial Sale in Korea and Up to $37.5 Million in Sales Related Milestones plus Royalties on Net Sales Nov 21, 2017, 06:30 ET CRANBURY, N.J., Nov. 21, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; “Palatin”) announced today that it has entered into

CRANBURY, N.J., Nov. 13, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2017.  Recent Highlights Bremelanotide – Under development for Hypoactive Sexual Desire Disorder

CRANBURY, N.J., Nov. 8, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2018 operating results on Monday, November 13, 2017  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 13,

CRANBURY, N.J., Sept. 25, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2017.  Recent and Fiscal Year Significant Highlights Bremelanotide

CRANBURY, N.J., Sept. 20, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter and fiscal year end 2017 operating results on Monday, September 25, 2017  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team